Optimizing the "Drug-like" Properties of Leads in Drug Discovery
Borchardt, Ronald T. (EDT); Kerns, Edward H. (EDT); Hageman, Michael J. (EDT); Thakker, Dhiren R. (EDT); Stevens, James L. (EDT)
ISBN 10: 0387340564 ISBN 13: 9780387340562
Verlag: Springer, 2006
Gebraucht
Hardcover
Verkäufer
GreatBookPrices, Columbia, MD, USA
Verkäuferbewertung 5 von 5 Sternen
AbeBooks-Verkäufer seit 6. April 2009
Dieser Artikel ist nicht mehr verfügbar.
Beschreibung
Beschreibung:
Unread book in perfect condition. Bestandsnummer des Verkäufers 5973388
Inhaltsangabe:
This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process.
Reseña del editor:
This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled "Optimizing the Drug-Like Properties of Leads in Drug Discovery," which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.
Bibliografische Details
Titel: Optimizing the "Drug-like" Properties of ...
Verlag: Springer
Erscheinungsdatum: 2006
Einband: Hardcover
Zustand: As New
Beste Suchergebnisse bei AbeBooks
Beispielbild für diese ISBN
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)
Verlag:
Springer (edition 2006), 2006
ISBN 10: 0387340564
ISBN 13: 9780387340562
Gebraucht
Hardcover
Anbieter: BooksRun, Philadelphia, PA, USA
Verkäuferbewertung 5 von 5 Sternen
Hardcover. Zustand: Good. 2006. It's a preowned item in good condition and includes all the pages. It may have some general signs of wear and tear, such as markings, highlighting, slight damage to the cover, minimal wear to the binding, etc., but they will not affect the overall reading experience. Bestandsnummer des Verkäufers 0387340564-11-1
Anzahl: 1 verfügbar
Beispielbild für diese ISBN
Optimizing the Drug-Like Properties of Leads in Drug Discovery [With CDROM]
Anbieter: ThriftBooks-Dallas, Dallas, TX, USA
Verkäuferbewertung 5 von 5 Sternen
Hardcover. Zustand: Good. No Jacket. Pages can have notes/highlighting. Spine may show signs of wear. ~ ThriftBooks: Read More, Spend Less. Bestandsnummer des Verkäufers G0387340564I3N00
Anzahl: 1 verfügbar
Foto des Verkäufers
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)
Anbieter: ebooks Keystone, Reading, PA, USA
Verkäuferbewertung 4 von 5 Sternen
Zustand: good. This book is in good condition, with minimal signs of wear and tear. Bestandsnummer des Verkäufers GWKV.0387340564.G
Anzahl: 1 verfügbar
Beispielbild für diese ISBN
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)
Anbieter: Lucky's Textbooks, Dallas, TX, USA
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. Bestandsnummer des Verkäufers ABLIING23Feb2215580172017
Anzahl: Mehr als 20 verfügbar
Beispielbild für diese ISBN
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Hardcover)
Verlag:
Springer-Verlag New York Inc., New York, NY, 2006
ISBN 10: 0387340564
ISBN 13: 9780387340562
Neu
Hardcover
Anbieter: Grand Eagle Retail, Bensenville, IL, USA
Verkäuferbewertung 5 von 5 Sternen
Hardcover. Zustand: new. Hardcover. Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, drug-like properties refer to the molecules physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. Based on the workshop, entitled "Pharmaceutical Profiling in Drug Discovery for Lead Selection", which took place in Whippany, on May 19-21, 2003. The workshop was focused on prediction, measurement, and utilization of drug-like properties during lead selection. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Bestandsnummer des Verkäufers 9780387340562
Anzahl: 1 verfügbar
Foto des Verkäufers
"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery"
Verlag:
Springer New York, Springer New York Aug 2006, 2006
ISBN 10: 0387340564
ISBN 13: 9780387340562
Neu
Hardcover
Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Buch. Zustand: Neu. Neuware -Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, ¿drug-like¿ properties refer to the molecule¿s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 524 pp. Englisch. Bestandsnummer des Verkäufers 9780387340562
Anzahl: 2 verfügbar
Foto des Verkäufers
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Print-on-DemandAnbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled 'Optimizing the Drug-Like Properties of Leads in Drug Discovery,' which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process. 524 pp. Englisch. Bestandsnummer des Verkäufers 9780387340562
Anzahl: 2 verfügbar
Beispielbild für diese ISBN
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery (Biotechnology: Pharmaceutical Aspects, IV)
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
Zustand: New. In. Bestandsnummer des Verkäufers ria9780387340562_new
Anzahl: Mehr als 20 verfügbar
Foto des Verkäufers
"Optimizing the \"Drug-Like\" Properties of Leads in Drug Discovery "
Verlag:
Springer New York, Springer New York, 2006
ISBN 10: 0387340564
ISBN 13: 9780387340562
Neu
Hardcover
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Verkäuferbewertung 5 von 5 Sternen
Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development. Bestandsnummer des Verkäufers 9780387340562
Anzahl: 1 verfügbar
Foto des Verkäufers
Optimizing the "Drug-Like" Properties of Leads in Drug Discovery
Anbieter: PsychoBabel & Skoob Books, Didcot, Vereinigtes Königreich
Verkäuferbewertung 5 von 5 Sternen
Hardcover. Zustand: Very Good. Hardcover (no jacket; printed boards). Includes CD-ROM on inside rear board. Very good condition. Half-title page has partially separated from binding. Boards' leading corners are a little bumped and scuffed. Pages are clear. TA. Used. Bestandsnummer des Verkäufers 510803
Anzahl: 1 verfügbar